Canaccord Genuity raised its price target on Edwards Lifesciences (NYSE: EW) to $155.00 (from $150.00) while maintaining a Buy rating, following the company's second quarter earnings announcement.

Analyst Jason Mills notes the company delivered a second quarter earnings per share and revenue results above consensus projections fueled by domestic TAVR business, growing 28% year over year, reflecting the analyst's suggestion to 'keep buying.'